Magforce AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
MagForce AG Maintains FY 2013 Financial Guidance
MagForce AG announced that based on current developments, the Company is reiterating its outlook for the fiscal year 2013 as published in the 2012 Annual Report. Given the Company's roll-out plan, it expects the net loss from operating activities to be higher than in 2012, largely due to the start of the new clinical glioblastoma study and to preparations for market entry in other countries.
Latest Key Developments in Biotechnology
- Omeros Corp prices $35.0 million public offering of common stock
- Navidea Biopharmaceuticals Inc announces presentation of Lymphoseek three-year recurrence and survival outcomes after Sentinel Lymph Node Biopsy in Patients with Breast Cancer and Melanoma
- Algeta appoints Thomas Ramdahl as new Managing Director
- Algeta ASA appoints chairman; to apply for delisting of shares from Oslo Stock Exchange
- Share this
- Digg this